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Abstract
Inherited renal cell carcinoma (RCC) is associated with multiple familial cancer syndromes
but most individuals with features of non-syndromic inherited RCC do not harbor vari-
ants in the most commonly tested renal cancer predisposition genes (CPGs). We investi-
gated whether undiagnosed cases might harbor mutations in CPGs that are not routinely
tested for by testing 118 individuals with features suggestive of inherited RCC (family
history of RCC, two or more primary RCC aged <60 years, or early onset RCC ≤46 years)
for the presence of pathogenic variants in a large panel of CPGs. All individuals had been
prescreened for pathogenic variants in the major RCC genes. We detected pathogenic
or likely pathogenic (P/LP) variants of potential clinical relevance in 16.1% (19/118) of
individuals, including P/LP variants in BRIP1 (n = 4), CHEK2 (n = 3), MITF (n = 1), and
BRCA1 (n = 1). Though the power to detect rare variants was limited by sample size the
frequency of truncating variants in BRIP1, 4/118, was significantly higher than in controls
(P = 5.92E-03). These findings suggest that the application of genetic testing for larger
inherited cancer gene panels in patients with indicators of a potential inherited RCC can
increase the diagnostic yield for P/LP variants. However, the clinical utility of such a
diagnostic strategy requires validation and further evaluation and in particular, confirma-
tion of rarer RCC genotype-phenotype associations is required.
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1 | INTRODUCTION
Renal cell carcinoma (RCC) is a group of human cancers derived from
renal epithelium that comprise a variety of histological and genetic
backgrounds. Worldwide, RCCs account for around 2.4% of all malig-
nancies, with a prevalence of about 4.4 per 100 000 individuals and a
cumulative lifetime risk (to age 75 years) of approximately 0.5%.1
Molecular genetic studies have identified multiple genetic causes for
RCC predisposition. The best recognized cause of familial RCC is the
dominantly inherited familial cancer syndrome von Hippel-Lindau
(VHL) disease caused by germline mutations in the VHL tumor sup-
pressor gene.2,3 Inactivating mutations in a number of tumor suppres-
sor genes including VHL, FH, FLCN, SDHB, and BAP1, activating
mutations in the MET proto-oncogene and constitutional chromosome
3 translocations are well established causes of inherited predisposition
to renal cancers.4 Though it has been suggested that 24% to 33% of
individuals with RCC may meet referral criteria for genetic testing,5
the majority of patients who undergo routine genetic testing for
germline variants in the “major inherited RCC genes” (ie, . VHL, FH,
FLCN, SDHB, BAP1, MET) do not have detectable pathogenic variants
(unpublished observations).
Recently, studies in a number of different human cancer types
have identified pathogenic variants in a wider range of cancer predis-
position genes (CPGs) than have been traditionally associated with
the cancer of interest.6,7 In addition, germline genetic testing of a
cohort of individuals with advanced RCC revealed 16% of individuals
presented with a pathogenic cancer-associated germline variant, of
which only about a third occurred in the widely recognized RCC-
associated genes.8 We hypothesized that applying a wider CPG test-
ing strategy to a cohort of affected individuals with features of
inherited RCC might increase the diagnostic yield of pathogenic/likely
pathogenic (P/LP) variants and we proceeded to investigate a large
panel of CPGs in 118 unrelated probands pre-screened for germline
mutations in VHL, MET, FLCN, SDHB, FH, and BAP1.
2 | MATERIALS AND METHODS
2.1 | Subjects
Individuals diagnosed with RCC referred to Regional Genetics Centres
for consideration of genetic testing were assessed for eligibility based
on the presence of clinical features associated with inherited RCC.
Individuals were recruited if they matched one or more of the follow-
ing criteria: (a) At least one first or second degree relative with RCC,
(b) no family history of RCC but two or more separate primary RCC
before age 60 years, or (c) diagnosed with RCC at age 45 years or less.
Assignment of groupings based on clinical criteria was carried out
hierarchically in the order given, where, for example, a patient with
bilateral RCC aged under 45 years with a family history of RCC would
be categorized as familial and a patient with bilateral RCC aged under
45 years without a family history of RCC would be categorized as
multiple RCC. For four individuals in whom the precise age at
diagnosis of RCC was not available the age at genetic testing was
used. Individuals with confirmed or likely pathogenic variants in BAP1,
FH, FLCN, MET, SDHB and VHL were excluded from the study. All
study participants gave written informed consent, and the study was
approved by the South Birmingham Research Ethics Committee.
2.2 | Molecular genetics studies
DNA was extracted from peripheral blood lymphocytes in a regional
genetics laboratory using standard techniques. A total of 100 samples
were analyzed using Illumina TruSight Cancer Sequencing Panel
(Illumina, San Diego, CA) on the Illumina MiSeq platform. Seventy five
probands (18 of whom were also analyzed by the Illumina TruSight
Cancer Sequencing Panel) had exome sequencing data generated by
Illumina TruSeq Exome library preparation on the Illumina HiSeq 4000
or Illumina NextSeq platform. In total 118 probands were analyzed by
panel and/or exome sequencing.
2.3 | Bioinformatics
Further details of bioinformatic protocols and methodology can be
found in the Appendix S1. FASTQ files for both case and ICR1000UK
exomes9 were aligned to genome reference GRCh38 using BWA-
MEM (version 0.7.15-r1140) with ALT-contig post-processing. PCR
duplicates were flagged by SAMtools rmdup (version 1.4.1) and vari-
ant calling carried out using GATK unified genotyper (version
3.7-0-gcfedb67). Variants from targeted sequencing panel and exome
datasets were called independently and a “virtual” panel applied to
the exome variants via vcftools, restricting the reported variants to
the Illumina TruSight Cancer sequencing panel target bed intervals
(with an additional 3 bp paddingAppendix S1). Full alignment and vari-
ant calling pipeline provided in Appendix S1. VCF files were filtered to
remove low quality calls and sequencing artefacts using vcftools and
in-house bioinformatics pipelines (supplementary Table S1). Lastly,
genomic regions were restricted to a total of 67 cancer-related genes
sub-selected from the original cancer gene panel as utilized previously7
which were targeted on the Illumina TruSight Cancer sequencing panel.
In addition, a single variant in MITF (rs149617956) was also assessed in
conjunction with the previously described genes due to previous associ-
ations with RCC risk10 (Supplementary Table S2, S3).
Variants passing quality filtering were annotated with ANNOVAR
to provide genomic region annotation, variant consequence, func-
tional in silico prediction, reference minor allele frequencies for
datasets of 1000 genomes project (1KG) and Exome Aggregation
Consortium (ExAC),11 and reported ClinVar data, where available. Var-
iants were selected by variant consequence, filtered to be rarer than
1% (minor AF < 0.01) in both 1KG and ExAC, in order to exclude com-
mon SNPs. In silico predictive metrics provided by ANNOVAR were
used to inform potential pathogenicity but were not used as filtering
cutoffs for candidate selection. ACMG guidelines12,13 were applied to
all candidate variants to determine clinical significance utilizing
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InterVar (version 20 180 827). Somatic variant calling was performed
jointly using both Strelka2 (version 2.9.10) and Mutect2 (version
3.7-0-gcfedb67) with annotation performed as described for germline
variant calls. The data that support the findings of this study are avail-
able on request from the corresponding author. The data are not pub-
licly available due to privacy or ethical restrictions.
Structural variant calling was performed using SvABA (version
1.1.3)14 to identify any large indels or structural variants within the
same genomic regions described for SNV calling. Full details of struc-
tural variant calling process are described in the Appendix S1.
2.4 | Statistical analysis
Proportion confidence intervals were calculated using R base function
binom.test at CI 95%, Odds ratios were calculated using the
oddsratio.fisher function in epitools package (version 0.5-10), and
two-tailed Fisher's exact tests were calculated using the fisher. test
function in base, using R (version 3.5.1).
3 | RESULTS
3.1 | Clinical features
The 118 unrelated individuals with RCC eligible for inclusion were
subdivided into three clinical subsets: 44 cases with a positive family
history and 74 sporadic cases comprising 30 cases with multifocal or
bilateral disease and 44 cases with early onset RCC only). Median age
of onset across all cases was 42 years (range 10-74) and 52 years
(range 29-74) in the familial cases, 48 years (range 31-72) in
multifocal/bilateral cases and 33 years (range 10-46) in early onset
cases). Histological subtype was available for 70 of 118 cases (59.3%)
and comprised of 68.6% clear cell RCC, 27.1% papillary RCC, and
4.29% chromophobe RCC. Summary of the distribution of clinical fea-
tures are given in Table 1 (full details in Supplementary Table S6).
3.2 | Variant filtering
A total of 1955 and 237 variants passed quality control filtering
requirements (Appendix S1) in the targeted sequencing and virtual
panel sets, respectively. After variant filtering (Appendix S1), a total of
159 variants were retained from the targeted sequencing and 25 vari-
ants were retained from the virtual panel sets, respectively. Variants
present in both sets were merged resulting in a total of 174 variants
across the targeted regions.
Analysis of the pathogenic or likely pathogenic (P/LP) variants iden-
tified in this set were divided into three categories subpanels based on
the clinical associations and inheritance patterns of the affected genes:
(a) Category I genes (n = 14) had a known association with syndromic or
non-syndromic RCC predisposition, (b) Category II genes (n = 18) were
those in which heterozygous pathogenic variants are known to be
associated with predisposition to multiple tumor types, and (c) Category
III genes (n = 35) which are associated with cancer predisposition when
there are biallelic pathogenic variants or those which have been associ-
ated with a single non-RCC tumor phenotype. List of targeted genomic
regions are listed in supplemental information Table S2.
Of the 174 variants assessed, 16 were classified as pathogenic or
likely pathogenic (P-LP) variants (three pathogenic, 13 likely pathogenic),
corresponding to four nonsense variants, three frameshift deletions,
one frameshift insertions, and eight nonsynonymous substitutions. The
16 variants were observed in 19 cases (16.1%; 95% CI: 9.98-23.0). P/LP
variants were equally distributed by count across the inherited subtypes
(nine variants in familial, six variants in early onset, and four variants
in bilateral/multifocal). All 16 P/LP variants are described in Table 2
and all 19 patients harboring the aforementioned variants in Table 3.
Structural variant calling, performed using SvABA, did not identify
any structural variants which passed quality control in the targeted
genomic regions.
3.3 | Detection of variants in category I: RCC
predisposition genes
As expected, no P/LP variants were detected in genes that had previ-
ously been analyzed before inclusion in this study (VHL, MET, FLCN,
TABLE 1 Summary of clinical features of individuals with








Early onset 33 (10-46)
Bi/multi 48 (31-74)
Case type, num. (%)
Familial 44 (37.2)
Early onset 44 (37.2)
Bi/multi 30 (25.4)
Histology, num. (%)
Clear cell RCC 48 (68.6)
Papillary RCC 19 (27.1)
Chromophobe RCC 3 (4.29)
Nonspecified RCC 48
Family history, num. (%)
First degree 27 (61.4)
Second degree 8 (18.2)
Unspecified 9 (20.5)
Abbreviation: RCC, renal cell carcinoma.
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SDHB, or BAP1) and only a single P/LP variant was identified in a gene
previously linked to RCC: a MITF nonsynonymous variant in
(NM_000248.3: c.952G>A: p.E318K) was identified in an individual
who presented with clear cell RCC at age 74 years and whose son
was reported to have presented with clear cell RCC at age 53 years.
Sequencing in the individual's unaffected brother did not reveal the
variant. Though this variant had been previously associated with pre-
disposition to RCC and melanoma 10 there was no reported family his-
tory of melanoma.
3.4 | Detection of variants in category II:
Multisite CPGs
Six distinct P/LP variants in three genes in which heterozygous
pathogenic variants are known to be associated with predisposition
to multiple non-RCC tumor types were identified in 8/118 cases.
Two category II genes, BRIP1 and CHEK2, harbored germline P/LP
variants in more than one proband. Four probands harbored a
heterozygous truncating variants in BRIP1 (two cases with
NM_032043.3: c.1871C>A: p.Ser624*, and one each with
NM_032043.3: c.1161dupA: p.Gln388Thrfs*7, and NM_032043.3:
c.2392C>T: p.Arg798*) (Supplementary Table S4). The four pro-
bands consisted of two familial cases and two multifocal/bilateral
cases. Age at diagnosis of RCC was 54, 64, 46, and 39 years and
these patients presented with papillary, two nonspecified, and clear
cell RCC, respectively (Table 3; Individuals RCC-043, RCC-074,
RCC-031, RCC-102). DNA from an affected family member (sec-
ond-degree relative) was available for one of the familial cases
(RCC-102) and the affected relative (who developed clear cell RCC
at age 57 years) harbored the BRIP1 nonsense variant (NM_032043.3:
c.2698G>A: p.Arg798*) identified in the proband (see Supplementary
Figure S1).
To compare the frequency of BRIP1 truncating variants (3.39%;
4/118) in the patient cohort to controls, the ICR1000UK control set
was analyzed for number of truncating variants. The ICR1000UK con-
trol cohort harbored BRIP1 truncating variants in 0.4% (4/999) of indi-
viduals (Supplementary Table S7), corresponding to an enrichment of
truncating variants in our cases (P = 5.92E-03, OR = 8.70, 95% CI:
1.60-47.4). In addition, evaluation of rare truncating variants in
BRIP1 detected in both the ExAC non-TCGA dataset and gnomAD
exome dataset15 revealed an estimated at 0.24% (123/51300) and
0.20% (252/124984), respectively, which results in a significant
enrichment in the case set (P = 2.19E-04, OR = 14.6, 95% CI: 3.85-
39.3 and P = 1.09E-04, OR = 17.4, 95% CI: 4.61-46.3). This associa-
tion is still present in ExAC non-TCGA and gnomAD exome datasets
after false discovery rate correction (Table 4). Finally, statistical com-
parison to data published by Easton et al16 also demonstrated a sta-
tistical enrichment in this series (P = 1.21E-04, OR = 18.2, 95% CI:
4.55-53.1) when compared to truncating variants in BRIP1 in breast
TABLE 3 Nineteen RCC samples carrying variants identified as pathogenic or likely pathogenic by ACMG guideline classifications assigned by
InterVar
Full Id Sex Subtype Histology Age Gene Variants
RCC-022 F Familial ccRCC 46 XPA XPA:c.464delT:p.Leu155*
RCC-030 M Early onset pRCC 40 BRCA1 BRCA1:c.4563delA:p.Lys1521Asnfs*5
RCC-023 F Bi/multi nsRCC 56 CHEK2 CHEK2:c.1263delT:p.Ser422Valfs*15
RCC-070 M Familial pRCC 44 XPC XPC:c.219delG:p.Val75Trpfs*4
RCC-074 F Familial nsRCC 64 BRIP1 BRIP1:c.1161dupA:p.Gln388Thrfs*7
RCC-011 M Familial nsRCC 58 CHEK2 CHEK2:c.1427C>T:p.Thr476Met
RCC-089 F Bi/multi nsRCC 40 ERCC2 ERCC2:c.2084G>A:p.Arg695His
RCC-025 F Familial ccRCC N/a ERCC2 ERCC2:c.1802G>A:p.Arg601Gln
RCC-052 F Bi/multi nsRCC 61 ERCC2 ERCC2:c.772C>T:p.Arg258Trp
RCC-068 M Familial ccRCC 74 MITF MITF:c.952G>A:p.Glu318Lys
RCC-059 M Bi/multi nsRCC 56 CHEK2 CHEK2:c.1263delT:p.Ser422Valfs*15
MUTYH MUTYH:c.1178G>A:p.Gly393Asp
RCC-088 F Early onset nsRCC 45 MUTYH MUTYH:c.527A>G:p.Tyr176Cys
RCC-099 M Early onset nsRCC 27 PMS2 PMS2:c.2066C>T:p.Thr689Ile
RCC-031 M Bi/multi nsRCC 46 BRIP1 BRIP1:c.1871C>A:p.Ser624*
RCC-001 M Familial nsRCC 38 PMS2 PMS2:c.11C>G:p.Ser4*
RCC-043 M Bi/multi pRCC 54 BRIP1 BRIP1:c.1871C>A:p.Ser624*
RCC-029 F Familial ccRCC 47 PMS2 PMS2:c.11C>G:p.Ser4*
RCC-096 F Early onset nsRCC 34 PMS2 PMS2:c.11C>G:p.Ser4*
RCC-102 M Familial ccRCC 39 BRIP1 BRIP1:c.2392C>T:p.Arg798*
Abbreviation: RCC, renal cell carcinoma.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SMITH ET AL. 11
cancer, found at a rate of 0.19% (28/14526) (Supplementary
Table S5).
A frameshift deletion in CHEK2 (NM_007194.4: c.1263delT: p.
Ser422Valfs*15) was identified in two individuals, both of whom pres-
ented with multifocal RCC in their fifth decade. The frameshift dele-
tion is considered to be pathogenic and has previously been detected
in both germline sequencing of breast17 and prostate cancer.18,19 An
additional CHEK2 nonsynonymous variant (NM_007194.4: c.1427C>T:
p.Thr476Met) was also identified in one individual with nonspecified
RCC at 58 years and had a reported family history. The variant falls
within the protein kinase domain of CHEK2 and in vitro studies had
reported loss of kinase activity and loss of DNA repair function.20,21 A
single individual with early onset papillary RCC at age 40 years was
found to carry a BRCA1 frameshift deletion in exon 15 (NM_007300.3:
c.4563delA: p.Lys1521Asnfs*5), which was absent in the noncancer
gnomAD data set.
A PMS2 nonsense variant was identified in three individuals, pur-
ported to occur within the fourth amino acid (NM_001322015:
c.11C>G: p.Ser4*) but on review was found only to affect non-
canonical isoform 14, resulting in an intronic substitution within the
canonical isoforms of PMS2. Furthermore, one individual was identi-
fied with a PMS2 nonsynonymous variant, occurring within the canon-
ical transcript (NM_000535: c.2066C>T: p.Thr689Ile). The PMS2
nonsynonymous substitution occurs within exon 12 resulting a threo-
nine to isoleucine substitution in a c-terminal dimerization domain.
The variant occurs as a singleton in the gnomAD data set15 and is
considered to be highly deleterious by multiple in silico predictive
tools.
3.5 | Analysis of tumors from cases with germline
BRIP1 truncating variants
Pathology blocks from RCC from two related patients with a truncat-
ing BRIP1 variant (BRIP1 NM_032043: c.2698G>A: p.Arg798*) were
available for analysis. The proband (RCC-102) presented with a
63 mm RCC at age 39 years. Histopathological review revealed that
the tumor contained some sheets of cells with clear cytoplasm, in
keeping with classification as a clear cell RCC. However, in many areas
the tumor showed very variable morphology, with a tubulo-papillary
architecture and areas where the cells had very abundant eosinophilic
cytoplasm (see Figure S2). The tumor cell nuclei were predominantly
WHO/ISUP grade 2, but some were interpreted as grade 3. There
was no sarcomatoid or rhabdoid morphology. There was no tumor
necrosis but there was a marked infiltrate of chronic inflammatory
cells within the tumor, including lymphocytes and macrophages.
Immunohistochemistry studies were performed and the tumor
showed positive staining for CA-IX, CD10, RCC, EMA, CD15,
CAM5.2, AMACR, MNF116, AE1/3, and Vimentin and there was very
weak and patchy staining for E-Cadherin. SDHB and FH expression
was retained. The tumor was negative for CD117, CK7, CK20, Mel-A,
and HMB45. This immunoprofile was in keeping with the diagnosis. In











































































































































































































































































































































































12 SMITH ET AL.
grade 3; pT1b pNX (UICC TNM eighth Edition); Leibovich score:
3. The affected relative (RCC102.1) had a >120 mm diameter tumor
with involvement of a renal vein tributary, stage pT3a with a
Leibovitch score = 5. Histopathological review showed typical mor-
phological features of a clear cell RCC (see Figure S2), with
WHO/ISUP grade 2 tumor cells and no tumor necrosis. Immunohisto-
chemistry was positive for Vimentin, RCC, CA-IX, AE1/3, and EMA
(focal). SDHB and FH expression were retained. Targeted somatic
gene panel sequencing was performed as described previously22 to
assess 68 cancer-related genes including several associated with RCC.
Only a single VHL variant in the tumor from the affected relative
(RCC102.1) was identified. The variant was consistent with clonal het-
erozygous inactivation of VHL resulting from a large deletion within
Exon 3. Both Strelka2 and Mutect2 called the somatic variant but
were not identically. Strelka2 called a single 30 bp nonframeshift dele-
tion (NM_000551; c.492_521del; p.Gln164_Asn174delinsHis) at a
variant allelic fraction of 0.31. Mutect2 called two separate but con-
tiguous frameshift deletions (NM_000551; c.492_501del; p.
Val165AlafsTer2 and NM_000551: c.503_522del: p.Ser168IlefsTer81)
at variant allelic fractions of 0.31 and 0.46, respectively. No additional
protein-altering somatic mutations were detected at variant allele
fraction greater than 10% in either tumor.
4 | DISCUSSION
We analyzed a cohort of 118 individuals with clinical characteristics
suggestive of inherited RCC (but no known genetic cause) for
germline variants in 68 cancer-related genes. This gene panel strategy
was previously used to analyse a large cohort of patients with multiple
primary tumors and in that study we found that there was a significant
diagnostic yield of P/LP variants in CPGs for which the tumor pheno-
type in the relevant patient was atypical.7
The only pathogenic variant identified in a category I gene was a
previously described nonsynonymous variant in MITF (c.952G>A: p.
E318K). The E318K variant was linked to non-syndromic RCC predis-
position in a cohort of individuals presenting with both RCC and mela-
noma in which variant carriers demonstrated a 5-fold increased risk
for melanoma, RCC, or both and functional studies demonstrated
MITF upregulation and differential expression of MITF target tran-
scripts.10,23 Subsequently the E318K variant was confirmed to be
associated with a melanoma predisposition24,25; however, the associa-
tion of MITF E318K with RCC predisposition has been less well stud-
ied and provides limited support for the association between RCC
predisposition and MITF E318K.26,27 In this instance, the identification
of MITF E318K in this cohort is difficult to interpret given the limited
sample sizes and the identification of only a single carrier. The cate-
gory I genes also included rarer RCC cancer predisposition genes such
as CDC73, PTEN, TSC1, and TSC2 that have been linked to syndromic
forms of inherited RCC and we did not identify pathogenic variants in
these genes (the cohort had been ascertained via clinical geneticists
and so we would have expected syndromic cases to have been identi-
fied prior to recruitment).
Several VUS variants were identified in TSC2 and MET. Three
variants in MET (NM_000245: c.T2543C: p.V848A, NM_000245:
c.G1406C: p.R469P, and NM_000245: c.A1336G: p.I446V) were pre-
sent at allelic frequencies lower than 8.5E-05, with in silico predic-
tions being variable, but none of the variants fall within the tyrosine
kinase domain associated with constitutional activation of c-MET,28,29
and none had been reported as somatic events in sporadic RCC based
on data from the catalogue of somatic mutations in cancer
(COSMIC).30
Six missense variants were identified in TSC2, associated with
tuberous sclerosis complex (MIM: 613254) which predisposes individ-
uals to renal angiomyolipomas and cysts, as well as hybrid or
oncocytic RCC in between 2% and 4% of cases.31,32 Histological infor-
mation was not available for these individuals to assess if they pres-
ented with histologies consistent with loss of TSC2. The predicted
pathogenicity of these missense variants, as well as the allele rarity, is
variable but two variants (NM_000548 c.G4657T: p.G1553C &
NM_000548: c.G5117A: p.R1706H) occur within the Rap GTPase
activating protein domain implicated in RHEB inhibition33 and one
variant (NM_000548: c.C2476A: p.L826M) arises in a Tuberin-type
domain, though its direct function is not known. None of the 6 variants
identified in TSC2 had been reported as somatic events in sporadic
RCC in COSMIC. All VUS variants are detailed in the Appendix S1.
Previously, segregation analysis of non-syndromic familial RCC
was found to be consistent with an autosomal dominant inheritance
pattern with incomplete penetrance.34 Together with recent findings
that the cancer phenotype of well-established cancer predisposition
genes may be wider than initially recognized6,7,35,36 this raised the
possibility that we might find pathogenic variants in category II genes
in individuals with features of inherited RCC. We identified patho-
genic variants in three category II genes (BRIP1, BRCA1, CHEK2) in
6.8% (8/118 probands), of our cohort (6.8% of familial cases, 9.1% of
multi/bilateral cases and 2.3% of early onset cases). Four probands
harbored truncating mutations in BRIP1. Pathogenic BRIP1 variants
were initially reported to predispose individuals to both breast and
ovarian cancers,37,38 though more recent evidence from epidemiologi-
cal studies of pathogenic BRIP1 variants in breast cancer have found
no association with breast cancer susceptibility.16,39 We note that the
potential link between RCC predisposition and pathogenic BRIP1 vari-
ants would be strengthened if any of the rare non-truncating BRIP1
variants identified in probands were to be proved to be pathogenic.
Only a single additional variant in BRIP1 (NM_032043: c.C1207T: p.
R403W) was identified as at least a VUS. This variant was enriched in
comparison to the gnomAD noncancer population (P = 7.0E-04), but
singleton variants in lower sample sizes are more difficult to accu-
rately assess. A recent study assessed the functional impact of several
novel or rare nonsynonymous variants40 and, though none of these
variants were present in our cohort, it highlights the potential for non-
truncating variants to contribute to cancer predisposition and need
for thorough functional evaluation of variants of uncertain
significance.
Pathogenic variants were also detected in two other DNA repair
genes, BRCA1 (n = 1) and CHEK2 (n = 3). While in this study we did
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not demonstrate statistical enrichment of CHEK2 P-LP variants in our
cohort of individuals with features of inherited RCC, joint assessment
of the frequency of P-LP variants in CHEK2 in this case series and our
cohort of individuals with multiple primary tumor-associated RCC that
we analyzed with a similar cancer predisposition gene panel strategy,7
demonstrated that P-LP CHEK2 variants are overrepresented after
multiple testing correction (7/192; P = 2.14E-04, FDR corrected = 1.77E-
02). This is also strengthened the association described by Carlo et al.
which reported an enrichment of germline CHEK2 variants in patients
with advanced RCC.8
The significance of the BRCA1 mutation in a single individual with
early onset papillary RCC is difficult to interpret. Germline BRCA1 and
BRCA2 variants have been reported previously and in a recent study
of 190 unrelated Chinese patients with RCC aged <45 years, analysis
of 23 CPGs revealed four RCC patients with pathogenic BRCA1
(n = 1) or BRCA2 (n = 3) germline variants.41 However, in BRCA1 and
BRCA2 mutation carriers ascertained through a personal and/or fam-
ily history of breast/ovarian cancer the risk of RCC had not been
reported to be increased.42
While some inherited RCC cases are caused by genes (eg, VHL,
MET, BAP1) which show high somatic alteration rates in sporadic RCC,
others inherited RCC genes (eg, FLCN and SDHB) do not display fre-
quent somatic alteration in sporadic RCC. BRCA1, CHEK2, or BRIP1
are frequently somatically altered in sporadic RCC in the TCGA
dataset (1.2%, 1%, and 1.1%, respectively) at a rate that would be
indicative of common somatic driver genes.43 However, BAP1, BRCA1,
BRCA2, BRIP1, and CHEK2 gene products have related functions in
DNA repair pathways that may make a common role in RCC predispo-
sition more plausible. BAP1 (BRCA1 associated protein) was originally
identified due to direct interactions with the RING finger domain of
BRCA1 and functions as a de-ubiquitinating enzyme. BAP1 has been
determined to form multiple protein complexes and known functions
include removal ubiquitin groups from histone H2A lysine 119 resi-
dues to regulate gene expression,44 modulation of DNA damage
repair by de-ubiquitinating BARD1 (which binds to BRCA1), indirectly
modulating the efficacy of BRCA1-driven DNA repair pathways,45
and mediates the recruitment of homologous recombination proteins
to DNA damage foci.46 Given the interconnected functions and path-
ways associated with CHEK2, BRIP1, and BRCA1, it can be hypothe-
sized that germline pathogenic variants in these gene might
predispose to a broader range of cancers in a manner similar to that
described with BAP1 predisposition syndrome, including RCC. Two
P-LP variants were also identified in PMS2 across four individuals
though the truncating variant present in three of these individuals
occurs in a noncanonical isoform, annotated as an intronic substitu-
tion. The PMS2 variants in this study were not independently con-
firmed and known issues regarding PMS2 pseudogenes47 make
interpretation more complex.
The observation that eight of the nine genes identified in this
study with P or LP variants are associated with DNA repair pathways
in some capacity could suggest a potential enrichment across all DNA
repair pathways but interpretation should be cautious given that can-
cer panels are biased towards DNA repair pathway components due
to frequent alterations in somatic sequencing, and several of these
genes only result in cancer presentation under autosomal recessive
inheritance, which was not demonstrated here.
Epidemiological studies have reported multiple risk factors includ-
ing smoking, obesity and hypertension48,49 but these features were
not reported in this study. An interesting further examination of the
results described herein is the relationship between what appear to
be generalized cancer predisposition genes, or at least rare causes of
cancers outside of the canonical cancer spectrum, and impact of envi-
ronmental factors in the resulting genotype-phenotype correlations.
In summary we found that in a cohort of patients with features
associated with inherited predisposition to RCC and no detectable
mutation in routinely tested RCC CPGs, extension of testing to a
larger CPG panel revealed pathogenic variants in CPGs associated
with multiple cancer types in a subset of patients. This finding is con-
sistent with previous studies of patients with early onset or advanced
RCC that have been analyzed by larger gene panels and with the
results of patients with multiple primary tumors7,8,43 If patients with
germline mutations in DNA repair genes, such as BRCA1, BRCA2,
BRIP1, and CHEK2 were shown to benefit from specific targeted ther-
apies there would be a clear case for incorporating a wider genetic
testing protocol into clinical care. However, we suggest that before
the implementation into routine clinical practice of wider CPG testing
for patients with potential non-syndromic inherited RCC proceeds,
further studies are required to establish a causal link between RCC
predisposition and pathogenic variants in BRIP1, BRCA1, BRCA2, and
CHEK2 and to determine more accurately renal cancer risks in patients
with pathogenic variants in these genes so that appropriate renal
screening protocols for asymptomatic gene carriers can be defined.
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